BETA


2008/0257(COD) Medicinal products for human use: pharmacovigilance of products

Progress: Procedure completed

RoleCommitteeRapporteurShadows
Lead ENVI MCAVAN Linda (icon: S&D S&D)
Former Responsible Committee ENVI
Committee Opinion ITRE RIVASI Michèle (icon: Verts/ALE Verts/ALE)
Committee Opinion IMCO TURMES Claude (icon: Verts/ALE Verts/ALE)
Former Committee Opinion ITRE Jens ROHDE (icon: ALDE ALDE)
Former Committee Opinion IMCO Philippe JUVIN (icon: PPE PPE), Matteo SALVINI (icon: ENF ENF)
Lead committee dossier:
Legal Basis:
TFEU 114-p1, TFEU 168-p4

Events

2010/12/31
   Final act published in Official Journal
Details

Corrigendum to Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products (Regulation first published in the OJ L 348 of 31.12.2010).

Article 1(7) should read:

In Article 16, paragraphs 1, 2 and 3 are replaced by the following:

3. The marketing authorisation holder shall ensure that the product information is kept up to date with the current scientific knowledge including the conclusions of the assessment and recommendations made public by means of the European medicines web-portal established in accordance with Article 26.

3a. In order to be able to continuously assess the risk-benefit balance, the Agency may at any time ask the marketing authorisation holder to forward data demonstrating that the risk-benefit balance remains favourable. The marketing authorisation holder shall answer fully and promptly any such request.

The Agency may at any time ask the marketing authorisation holder to submit a copy of the pharmacovigilance system master file. The marketing authorisation holder shall submit the copy at the latest seven days after receipt of the request.

2010/12/15
   CSL - Draft final act
Documents
2010/12/15
   CSL - Final act signed
2010/12/15
   EP - End of procedure in Parliament
2010/11/29
   EP/CSL - Act adopted by Council after Parliament's 1st reading
2010/11/29
   CSL - Council Meeting
2010/10/13
   EC - Commission response to text adopted in plenary
Documents
2010/09/22
   EP - Results of vote in Parliament
2010/09/22
   EP - Decision by Parliament, 1st reading/single reading
Details

The European Parliament adopted by 559 votes to 7, with 12 abstentions, a legislative resolution on the proposal for a regulation of the European Parliament and of the Council amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency.

The Parliament adopted its position at first reading under the ordinary legislative procedure (formerly known as the codecision procedure). The amendments adopted in plenary are the result of a compromise reached between the European Parliament and the Council. They amend the Commission’s position as follows:

Strengthened Risk Assessment Committee : in order to ensure harmonised responses across the Union to safety concerns regarding medicinal products for human use, the Committee for Medicinal Products for Human Use and the coordination group established by Directive 2001/83/EC on the Community code relating to medicinal products for human use should rely on the recommendation of the Pharmacovigilance Risk Assessment Committee on any question relating to the pharmacovigilance of medicinal products for human use.

It is appropriate that the Pharmacovigilance Risk Assessment Committee should give a recommendation as part of any Union-wide post-authorisation assessment based on pharmacovigilance data relating to medicinal products as well as on the agreement and monitoring of the risk management systems. Such Union-wide assessments should follow the procedures laid down in Directive 2001/83/EC also for medicinal products that were authorised through the centralised procedure.

Market authorisation : post authorisation efficacy and safety studies : the amended text stipulates that it is necessary from a public health perspective to complement the data available at the time of authorisation with additional data about the safety and, in certain cases, also about the efficacy of medicinal products authorised. The Commission should therefore be empowered to require the marketing authorisation holder to conduct post-authorisation studies on safety and on efficacy. It should be possible to impose this requirement at the time of granting the marketing authorisation or later, and it should be part of the marketing authorisation. These additional studies may be aimed at collecting data to enable the assessment of safety or efficacy of medicinal products in everyday medical practice. The supervisory authorities for pharmacovigilance may, as considered necessary, conduct pre-authorisation pharmacovigilance inspections to verify the accuracy and successful implementation of the pharmacovigilance system as described by the applicant in support of the application.

Products authorised subject to additional monitoring : some medicinal products are authorised subject to additional monitoring. This includes all medicinal products with a new active substance and biological medicinal products including biosimilars for which pharmacovigilance activities are prioritised. This may also apply, at the request of the competent authorities, to specific products, subject to the requirement to conduct a post-authorisation safety study or subject to conditions or restrictions with regard to the safe and effective use of the medicinal product that will be specified in the risk management plan.

Risk management plans are normally required for new active substances, biosimilars, medicinal products for paediatric use and for products involving a significant change in the marketing authorisation, including a new manufacturing process of a biotechnologically-derived product. Products subject to additional monitoring should be identified as such by a black symbol , which will be selected by the Commission on a recommendation by the Pharmacovigilance Risk assessment Committee, and a relevant standard explanatory sentence on the summary of product characteristics and on the patient information leaflet, and a publicly available list of such medicinal products should be kept up to date by the Agency.

Data protection : this Regulation shall apply without prejudice to Directive 95/46/EC on the protection of individuals with regard to the processing of personal data and on the free movement of such data and Regulation (EC) No 45/2001 on the protection of individuals with regard to the processing of personal data by the Union institutions and bodies and on the free movement of such data.

In order to detect, assess, understand and prevent adverse reactions, identify and take actions to reduce risks and increase benefits from medicinal products for the purpose of safeguarding public health, it should be possible to process personal data within the Eudravigilance system while respecting EU data protection legislation.

Tasks of the Agency : the amended text specifies that the Regulation and Directive amending Directive 2001/83/EC on the Community Code relating to medicinal products for human use widen the task of the Agency with regard to pharmacovigilance, including literature monitoring, improved information technology tools and provision of more information to the general public. The Agency should be enabled to fund these activities from fees paid by marketing authorisation holders. These fees should not cover tasks carried out by national competent authorities for which such authorities charge fees in accordance with the provisions of Directive 2001/83/EC.

Uniform conditions : a recital states that uniform conditions be established as concerns the contents and maintenance of the pharmacovigilance system master file, as well the minimum requirements of the quality system for the performance of pharmacovigilance activities by the national competent authorities and marketing authorisation holders, the use of internationally agreed terminology, formats and standards for the conduct of pharmacovigilance, and the minimum requirements for the monitoring of data in the Eudravigilance database to determine whether there are new or changed risks.

The format and content of electronic transmission of suspected adverse reactions by Member States and marketing authorisation holders, the format and content of electronic periodic safety update reports and risk management plans and the format of protocols, abstracts and final study reports for the post-authorisation safety studies should also be established. In this respect, pending the adoption of a new Regulation based on Article 291 of the TFEU, Council Decision 1999/468/EC of 28 June 1999 laying down the procedures for the exercise of implementing powers conferred on the Commission continues to apply, with the exception of the regulatory procedure with scrutiny, which is not applicable.

Executive Director of the Agency : the Executive Director of the Agency shall ensure appropriate coordination between the Committee for Advanced Therapies and the other Committees of the Agency, in particular the Committee for Medicinal Products for Human Use, the Pharmacovigilance Risk Assessment Committee and the Committee for Orphan Medicinal Products, their working parties and any other scientific advisory groups.

Documents
2010/09/21
   EP - Debate in Parliament
2010/05/10
   EP - Committee report tabled for plenary, 1st reading/single reading
Documents
2010/05/10
   EP - Committee report tabled for plenary, 1st reading/single reading
Documents
2010/04/27
   EP - Vote in committee, 1st reading/single reading
Details

The Committee on the Environment, Public Health and Food Safety adopted the report by Linda MACAVAN (S&D, UK) on the proposal for a regulation of the European Parliament and of the Council amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. It recommended that the European Parliament’s position at first reading under the ordinary legislative procedure (formerly known as the codecision procedure) should be to amend the Commission proposal as follows:

A Pharmacological Risk Assessment Committee (PRAC) with greater powers: in order to ensure harmonised responses across the Community to safety concerns regarding medicinal products for human use, the Committee for Medicinal Products for Human Use and the coordination group established by Directive 2001/83/EC on the Community code relating to medicinal products for human use should rely on the recommendation of the Pharmacovigilance Risk Assessment Committee on any question relating to the pharmacovigilance of medicinal products for human use.

The CHMP shall adopt an opinion which differs from the recommendation of the Pharmacovigilance Risk Assessment Committee, only where there exist strong scientific and public health grounds for doing so. The CHMP shall explain such grounds in a justification to be annexed to its opinion.

Post-authorisation safety and efficacy studies : after the granting of a marketing authorisation, the Agency may require a marketing authorisation holder to conduct a post-authorisation safety study, or post-authorisation safety and efficacy studies where important questions relating to the efficacy of a product remain; or when scientific advances in the understanding of the disease or in the clinical methodology would significantly change previous efficacy evaluations. For this purpose the Commission shall provide guidelines. The Commission shall also, based on data received from the Agency and Member States, produce a report focusing on the concept of Clinical Effectiveness, studies and data required and methodologies for assessing it.

Renewal of marketing authorisation : the committee deleted the words « insufficient exposure to the product » as a criterion for restricting renewal to a five-year period. The benefits of a harmonised and simplified approach pursued in the current proposal should be preserved. The new proposal should not regress on improvements introduced by the previous revision of the medicines legislation which aimed at reducing the number of renewal procedures.

Pharmacovigilance: the report adds that Member States shall support the development of the expertise of national and regional pharmacovigilance centres. National competent authorities should collect the reports from those centres and should then transfer data to the Eudravigilance database.

The Agency shall work together with all stakeholders, including research institutions, healthcare professionals, and patient and consumer organisations, in order to define the "appropriate level of access" to the Eudravigilance database.

The Agency, in collaboration with the Member States and all relevant stakeholders, shall develop standard structured forms and procedures, including web-based forms, for the reporting of suspected adverse reactions by health-care professionals and patients. To ensure the identification of biological medicinal products prescribed, dispensed or sold in the territory of the Union, the standard forms and procedures shall include the name of the MAH (marketing authorisation holder), the INN(international non-proprietary name), the name of the medicinal product and the batch number. The Agency shall also make available to the public other means for patients to report undesirable effects, such as a dedicated telephone number or special email address All citizens of the Union shall have the option of submitting online declarations in their mother tongue.

The Agency must make public the declaration of committee members’ interests and agendas for, and records of, each meeting, accompanied by decisions taken. It must also make public the link to the Agency's EudraPharm database which must include the most up-to-date electronic version of the package leaflet and summary of product characteristics for all existing and new medicinal products authorised in accordance with the Regulation and with Directive 2001/83/EC, as well as a link to the Agency's European Public Assessment Report summary database which publishes information sheets on centrally authorised products. These two resources shall be publicised to the general public by the Agency or the competent authorities.

The Agency shall monitor all medical literature for reports of suspected adverse reactions to medicinal products for human use containing well established active substances.

Assessment report following periodic safety update reports : PRAAC shall formulate a recommendation for the Committee for Medicinal Products for Human Use on the basis of the assessment report. The CHMP shall adopt an opinion which differs from the recommendation of the Pharmacovigilance Risk Assessment Committee, only where there exist strong scientific and public health grounds for doing so. The CHMP shall explain such grounds in a justification to be annexed to its opinion.

Public hearings : in assessing updates to the risk management systems, the Pharmacovigilance Risk Assessment Committee may hold a public hearing. Public hearings shall be announced by means of the European medicines safety web-portal. The announcement shall include information on how marketing authorisation holders and the public can participate. The Agency shall provide the opportunity, to all those who request it, to participate in the hearing either in person or through the use of web-based technology. Where a marketing authorisation holder or another person intending to submit information has commercially confidential data relevant to the issue of the procedure, he may request that he be allowed to present those data to the Pharmacovigilance Risk Assessment Committee in a non-public hearing.

Lastly, the committee amended provisions relating to the composition of the Pharmacovigilance Risk Assessment Advisory Committee and stressed that its independence must be guaranteed.

2010/04/16
   EP - Committee opinion
Documents
2010/03/01
   EP - Amendments tabled in committee
Documents
2010/02/24
   EP - Committee opinion
Documents
2009/12/17
   EP - Committee draft report
Documents
2009/11/30
   CSL - Debate in Council
Details

On the basis of progress reports, the Presidency informed the Council of the state of play in the negotiations on two parts of the "pharmaceutical package": preventing falsified medicines from entering into the legal supply chain of medicinal products and the strengthening and rationalising of the current pharmacovigilance system.

Under the Swedish Presidency, the preparatory bodies of the Council pursued their work with high priority on these two parts of the package.

1) Concerning the draft directive on preventing the entry into the legal supply chain of falsified medicinal products , the working group reached tentative agreement on a number of technical aspects, including:

· the definition of "falsified medicinal products";

· the proposed definition of ''trading of medicinal products'' has been changed to ''brokering of medicinal products'' and amended, thereby clarifying which actors in the supply chain should be subject to the responsibilities of brokers. The proposed introduction of obligations for brokers aim to reinforce the traceability of medicinal products;

· a clarification of the relationship between the proposed new provisions in Directive 2001/83/EC and Community legislation on intellectual property rights.

Other elements of the proposal still need further discussion, notably with regard to the strengthening of controls of non active substances used in pharmaceuticals (excipients) and the proposed safety features aiming to render falsification more difficult.

The proposal includes provisions requiring the accreditation of third party auditors of Good Manufacturing Practices and Good Distribution Practices. A majority of delegations object to accreditation, since they maintain that such a system could result in a transfer of responsibility from manufacturers and importers as well as make enforcement by national competent authorities more difficult. The Presidency has therefore proposed to delete the provisions regarding accreditation from the text. Some delegations have expressed an interest in the possibility of establishing third party accreditation at a national level.

2) Concerning the proposals for a regulation and a directive on strengthening the EU system for the safety monitoring of medicinal products ("pharmacovigilance"), the working group reached tentative agreement on a number of questions including:

· a clarification of the relation between the proposed new provisions in Directive 2001/83/EC and Regulation (EC) 726/2004 on the one hand and the Community legislation on protection of personal data on the other hand;

· a strengthening of the role of the Pharmacovigilance Risk Assessment Committee (PRAC) in relation to the Committee for Medicinal Products for Human Use and to the Coordination Group set up by Article 27 of Directive 2001/83/EC (CMD), including an obligation for these last two bodies to explain any differences in opinion compared to the PRAC;

· a change in the composition of the PRAC and in the method for nominating the PRAC members so that all Member States will be represented;

· the inclusion of a requirement for the Agency, in collaboration with the Member States and the Commission, to draw up functional specifications for the Eudravigilance database which will take account of the role and experience of national competent authorities for pharmacovigilance. The new reporting obligations to Eudravigilance will not apply until these specifications are met and to this end a transitional period is envisaged;

· the legal status of CMD opinions and how they are implemented in Member States. Here, text redrafting proposals are under legal scrutiny.

The Working Party has continued to discuss other central provisions of the proposals, mainly in relation to the Community Procedure and Referrals, the Recording and Reporting of adverse reactions, the Periodic Safety Update Reports and the Post Authorisation Safety Studies.

A number of issues still require further examination, such as the recording and reporting of adverse reactions and the proposed list of medicinal products for human use under intensive monitoring.

At this stage, all delegations have a general scrutiny reservation on the entire proposal while the Danish, Maltese and United Kingdom delegations have parliamentary scrutiny reservations.

3) With regard to the third part of the "pharmaceutical package", the proposals for a regulation and a directive concerning information for the general public on medicinal products, the Presidency recalled the strong concerns of many Member States. The Commission made it clear that it is prepared to show flexibility in order to find a common basis for the future negotiations.

Documents
2009/11/30
   CSL - Council Meeting
2009/10/19
   EP - Committee referral announced in Parliament, 1st reading/single reading
2009/09/28
   EP - TURMES Claude (Verts/ALE) appointed as rapporteur in IMCO
2009/09/16
   EP - RIVASI Michèle (Verts/ALE) appointed as rapporteur in ITRE
2009/09/10
   EP - MCAVAN Linda (S&D) appointed as rapporteur in ENVI
2009/06/10
   ESC - Economic and Social Committee: opinion, report
Documents
2009/04/22
   EDPS - Document attached to the procedure
Details

OPINION OF THE EUROPEAN DATA PROTECTION SUPERVISOR on the proposal for a Regulation of the European Parliament and of the Council amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and on the proposal for a Directive of the European Parliament and of the Council amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use.

Recall : on 10 December 2008, the Commission adopted two proposals relating to the amendment of the actual pharmacovigilance system. The general intention of the two proposals is to remedy these weaknesses and to improve and strengthen the Community pharmacovigilance system with the overall objective of better protecting public health, ensuring proper functioning of the internal market and simplifying the current rules and procedures (see COD/2008/0260 ). The overall operation of the current pharmacovigilance system relies on the processing of personal data. These data are included in the adverse drug reactions reporting and can be considered as data relating to health of the persons concerned since they reveal information about drug use and associated health problems.

Processing of such data is subject to strict data protection rules as laid down in Regulation (EC) No 45/2001 on the protection of individuals with regard to the processing of personal data by the Community institutions and bodies and on the free movement of such data and Directive 95/46/EC on the protection of individuals with regard to the processing of personal data and on the free movement of such data.

Despite this, no reference to data protection is included in the current text of Regulation (EC) No 726/2004 and Directive 2001/83/EC, except for one specific reference in the Regulation. The EDPS regrets that data protection aspects are not considered within the proposed amendments and that he was not formally consulted on both proposals for amendments. The EDPS recommends that a reference to this opinion is included in the preamble of both proposals.

Content of the Opinion : this Opinion will first proceed with a simplified explanation of the system of pharmacovigilance in the EU as it follows from Regulation (EC) No 726/2004 and Directive 2001/83/EC in their present state. Subsequently, the necessity of processing of personal data in the context of pharmacovigilance will be analysed. After this, the proposals of the Commission for improving the current and envisaged legal framework will be discussed and recommendations will be made on how to ensure and improve the data protection standards.

Conclusions and recommendations : the EDPS takes the view that the lack of a proper assessment of the data protection implications of pharmacovigilance constitutes one of the weaknesses of the current legal framework set out by Regulation (EC) No 726/2004 and Directive 2001/83/EC . The current amendment of Regulation (EC) No 726/2004 and Directive 2001/83/EC should be seen as an opportunity to introduce data protection as a full-fledged and important element of pharmacovigilance.

A general issue to be addressed thereby is the actual necessity of processing personal health data at all stages of the pharmacovigilance process. As explained in this Opinion, the EDPS seriously doubts this need and urges the legislator to reassess it at the different levels of the process. It is clear that the purpose of pharmacovigilance can in many cases be achieved by sharing information on adverse effects which is anonymous in the meaning of the data protection legislation. Duplication of reporting can be avoided through the application of well structured data reporting procedures already at national level.

The proposed amendments envisage a simplified reporting system and a strengthening of the EudraVigilance database . The EDPS has explained that these amendments lead to increased risks for data protection, especially when it involves the direct reporting of patients to the EMEA or the EudraVigilance database.

In this respect, the EDPS:

strongly advocates a decentralised and indirect reporting system whereby communication to the European webportal is coordinated through using the national webportals; emphasises that privacy and security should be part of the design and implementation of a reporting system through the use of web-portals (‘privacy by design’); underlines that once data concerning health about identified or identifiable natural persons is processed, the person responsible for such processing should comply with all the requirements of the Community data protection legislation.

More specifically, the EDPS recommends :

to include a reference to this Opinion in the preamble of both proposals, to introduce in both Regulation (EC) No 726/2004 and Directive 2001/83/EC a recital stating the importance of data protection in the context of pharmacovigilance, with references to the relevant Community legislation; to introduce in Regulation (EC) No 726/2004 and Directive 2001/83/EC a new Article having a general nature which states that: (i) the provisions of Regulation (EC) No 726/2004 and Directive 2001/83/EC are without prejudice to the rights and obligations stemming from the provisions of Regulation (EC) No 45/2001 and Directive 95/46/EC respectively, with specific reference to Article 10 of Regulation (EC) No 45/2001 and Article 8 of Directive 95/46/EC respectively; (ii) identifiable health data shall only be processed when strictly necessary and parties involved should assess this necessity at every single stage of the pharmacovigilance process; to include in the proposed Article 24(2) of Regulation (EC) No 726/2004 a sentence stating that the accessibility of the EudraVigilance database shall be regulated in conformity with the rights and obligations stemming from the Community legislation on data protection; to add a paragraph to the proposed Article 24 stating that measures shall be put in place which ensure that the data subject can exercise his right of access to personal data concerning him as provided for by Article 13 of Regulation (EC) No 45/2001; to add to the proposed Article 101 of Directive 2001/83/EC a paragraph which states that in case of processing of personal data the individual shall be properly informed in accordance with Article 10 of Directive 95/46/EC; to include in the newly proposed Articles 25 and 26 of Regulation (EC) No 726/2004 and Article 106 of Directive 2001/83/EC, which deal with the development of a reporting system for adverse effects through the use of web- portals, an obligation to incorporate proper privacy and security measures at an even level across Member States, taking into account the basic principles of confidentiality, integrity, accountability and availability of data.

2009/01/13
   EP - Committee referral announced in Parliament, 1st reading/single reading
2008/12/10
   EC - Document attached to the procedure
2008/12/10
   EC - Document attached to the procedure
2008/12/10
   EC - Legislative proposal published
Details

PURPOSE: to improve the functioning of Community rules on the pharmacovigilance of medicinal products for human use, with the overall objectives of better protecting public health, ensuring proper functioning of the internal market and simplifying the current rules and procedures.

PROPOSED ACT: Directive of the European Parliament and of the Council.

CONTENT: it is estimated that 5% of all hospital admissions are due to an adverse drug reaction, that 5% of all hospital patients suffer an adverse drug reaction and adverse drug reactions are the fifth most common cause of hospital death. Some adverse reactions will only be detected after a medicine has been authorised and the full safety profile of medicinal products can only be known once they have entered the market.

Community rules so far adopted have made a major contribution to the achievement of the objective that medicinal products authorised to be placed on the Community market are continuously monitored as regards their safety. However, in the light of the experience acquired and following an assessment by the Commission of the Community system of pharmacovigilance, it has become clear that new measures are necessary to improve the operation of the Community rules on the pharmacovigilance of medicinal products for human use.

Therefore, the proposals aim at the strengthening and rationalizing the Community pharmacovigilance system of medicinal products for human use through the amendment of the two legal acts governing this field, i.e. Directive 2001/83/EC (see COD/2008/0260 ) and Regulation (EC) No 726/2004. The specific objectives are:

providing for clear roles and responsibilities for the key responsible parties and clear obligations against which they perform their roles; rationalising EU decision-making on drug safety issues; strengthening medicines safety transparency and communication; strengthening companies' pharmacovigilance systems; ensuring the proactive and proportionate collection of high quality data relevant to the safety of medicines through risk management and structured data collection; involving stakeholders in pharmacovigilance; simplification of the current Community pharmacovigilance procedures.

The key elements of the proposals can be summarised as follows:

Clear roles and responsibilities :

the key tasks of the Agency in the area of pharmacovigilance are overall maintained, but the Agency's coordinating role at the centre of the Community pharmacovigilance system is reinforced; the Member States should remain core to the operation of pharmacovigilance in the Community, with increased cooperation and work-sharing mechanisms; the pharmacovigilance responsibilities of marketing authorisation holders are also clarified, in particular as regards the scope of the obligation of marketing authorisation holders to continuously monitor the safety of products to ensure that all information available is brought to the attention of the authorities; a new scientific committee responsible for pharmacovigilance is created within the Agency: the Pharmacovigilance Risk Assessment Advisory Committee. This Committee is intended to play a key role in the pharmacovigilance assessments in the Community; the mandate of the coordination group composed of Member States representatives is enhanced; the Community procedure for the assessment of serious safety issues for nationally authorised products is stream-lined through clear and binding initiation criteria for the Member States.

Transparency and communication in terms of drug safety issues :

strengthening of the Eudravigilance database, which should become the single point of receipt of pharmacovigilance information for medicinal products for human use authorised in the Community; Community coordination of communication about safety issues and establishment of a European medicines safety web-portal; introduction of a new ‘key information' section in the summary of the product characteristics and the package leaflet which accompany every medicinal product placed on the Community market.

Pharmacovigilance obligations of the marketing authorisation holder : the proposals simplify the requirement that a ‘detailed description of the pharmacovigilance system’ be submitted in marketing authorisation applications. In the marketing authorisation application, only key elements of the pharmacovigilance system should be submitted, but this is balanced with a requirement for companies to maintain a detailed pharmacovigilance system master file on site.

Risk management planning and non-interventional safety studies :

the establishment of a risk management system for each medicinal product to be newly authorised in the Community (or for existing products on the basis of safety concerns), which should be proportionate to the identified risks, potential risks, and the need for additional information on the medicinal product; the establishment of harmonised guiding principles and a procedure for the supervision of non-interventional post-authorisation safety studies (i.e. safety studies of authorised products that are not clinical trials), in particular to ensure that they are non promotional, and the follow-up of any safety data generated in such studies.

Adverse drug reaction case reports : the proposals are intended to make reporting proportionate to risks, to empower patients to report their side effects, and to ensure that overdoses and medication errors are reported. The following has therefore been proposed:

simplification of adverse reaction reporting by providing that all adverse reaction data are reported directly to the Eudravigilance database; requiring the Agency to assume the role of monitoring scientific literature by the Agency and to enter case reports of adverse effects into the Eudravigilance database; clarification of the definition of adverse drug reaction to make clear that companies report medication errors that result in an adverse reaction to the competent authorities for medicines and ensure that all the relevant Member State authorities share data; clarification of the legal basis for patients to report suspected adverse drug reactions.

Periodic safety update reports and other safety related assessments : the proposals simplify periodic safety update report submission by industry and make it proportional to the knowledge about the safety/risk of the product. They introduce work-sharing mechanisms for the assessments, with a prominent role in all cases by the Pharmacovigilance Risk Assessment Advisory Committee, and faster updating of product information through the establishment of clear procedures.

Documents

Activities

AmendmentsDossier
118 2008/0257(COD)
2010/02/05 ITRE 14 amendments...
source: PE-438.505
2010/02/12 IMCO 31 amendments...
source: PE-438.462
2010/03/01 ENVI 73 amendments...
source: PE-438.413

History

(these mark the time of scraping, not the official date of the change)

committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
rapporteur
name: MCAVAN Linda date: 2009-09-10T00:00:00 group: Progressive Alliance of Socialists and Democrats abbr: S&D
committees/0
type
Responsible Committee
body
EP
associated
False
committee_full
Environment, Public Health and Food Safety
committee
ENVI
date
2009-09-10T00:00:00
rapporteur
name: MCAVAN Linda group: Progressive Alliance of Socialists and Democrats abbr: S&D
committees/1/date
    committees/2
    type
    Committee Opinion
    body
    EP
    associated
    False
    committee_full
    Industry, Research and Energy
    committee
    ITRE
    rapporteur
    name: RIVASI Michèle date: 2009-09-16T00:00:00 group: Greens/European Free Alliance abbr: Verts/ALE
    committees/2
    type
    Committee Opinion
    body
    EP
    associated
    False
    committee_full
    Industry, Research and Energy
    committee
    ITRE
    date
    2009-09-16T00:00:00
    rapporteur
    name: RIVASI Michèle group: Greens/European Free Alliance abbr: Verts/ALE
    committees/3
    type
    Committee Opinion
    body
    EP
    associated
    False
    committee_full
    Internal Market and Consumer Protection
    committee
    IMCO
    rapporteur
    name: TURMES Claude date: 2009-09-28T00:00:00 group: Greens/European Free Alliance abbr: Verts/ALE
    committees/3
    type
    Committee Opinion
    body
    EP
    associated
    False
    committee_full
    Internal Market and Consumer Protection
    committee
    IMCO
    date
    2009-09-28T00:00:00
    rapporteur
    name: TURMES Claude group: Greens/European Free Alliance abbr: Verts/ALE
    committees/4/date
      committees/5/date
        docs/2/docs/0/url
        Old
        https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:C:2009:229:TOC
        New
        https://eur-lex.europa.eu/JOHtml.do?uri=OJ:C:2009:229:SOM:EN:HTML
        docs/8/docs/0/url
        Old
        http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2010-153&language=EN
        New
        http://www.europarl.europa.eu/doceo/document/A-7-2010-0153_EN.html
        docs/9/body
        EC
        events/0/docs/0/url
        Old
        http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2008/0664/COM_COM(2008)0664_EN.pdf
        New
        http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2008/0664/COM_COM(2008)0664_EN.pdf
        events/5/docs/0/url
        Old
        http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2010-153&language=EN
        New
        http://www.europarl.europa.eu/doceo/document/A-7-2010-0153_EN.html
        events/8/docs/0/url
        Old
        http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2010-331
        New
        http://www.europarl.europa.eu/doceo/document/TA-7-2010-0331_EN.html
        events/12/docs/3/url
        Old
        https://eur-lex.europa.eu/JOHtml.do?uri=OJ:L:2012:201:SOM:EN:HTML
        New
        https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2012:201:TOC
        activities
        • date: 2008-12-10T00:00:00 docs: url: http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2008/0664/COM_COM(2008)0664_EN.pdf title: COM(2008)0664 type: Legislative proposal published celexid: CELEX:52008PC0664:EN body: EC commission: DG: url: http://ec.europa.eu/dgs/health_consumer/index_en.htm title: Health and Consumers Commissioner: DALLI John type: Legislative proposal published
        • date: 2009-01-13T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading committees: body: EP responsible: True committee: ENVI date: 2009-09-10T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: S&D name: MCAVAN Linda body: EP responsible: True committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: False committee: IMCO date: 2009-09-28T00:00:00 committee_full: Internal Market and Consumer Protection rapporteur: group: Verts/ALE name: TURMES Claude body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO body: EP responsible: False committee: ITRE date: 2009-09-16T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: Verts/ALE name: RIVASI Michèle body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE
        • date: 2009-10-19T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading committees: body: EP responsible: True committee: ENVI date: 2009-09-10T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: S&D name: MCAVAN Linda body: EP responsible: True committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: False committee: IMCO date: 2009-09-28T00:00:00 committee_full: Internal Market and Consumer Protection rapporteur: group: Verts/ALE name: TURMES Claude body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO body: EP responsible: False committee: ITRE date: 2009-09-16T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: Verts/ALE name: RIVASI Michèle body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE
        • body: CSL meeting_id: 2980 docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=2980*&MEET_DATE=30/11/2009 type: Debate in Council title: 2980 council: Employment, Social Policy, Health and Consumer Affairs date: 2009-11-30T00:00:00 type: Council Meeting
        • date: 2010-04-27T00:00:00 body: EP committees: body: EP responsible: True committee: ENVI date: 2009-09-10T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: S&D name: MCAVAN Linda body: EP responsible: True committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: False committee: IMCO date: 2009-09-28T00:00:00 committee_full: Internal Market and Consumer Protection rapporteur: group: Verts/ALE name: TURMES Claude body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO body: EP responsible: False committee: ITRE date: 2009-09-16T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: Verts/ALE name: RIVASI Michèle body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE type: Vote in committee, 1st reading/single reading
        • date: 2010-05-10T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2010-153&language=EN type: Committee report tabled for plenary, 1st reading/single reading title: A7-0153/2010 body: EP committees: body: EP responsible: True committee: ENVI date: 2009-09-10T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: S&D name: MCAVAN Linda body: EP responsible: True committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: False committee: IMCO date: 2009-09-28T00:00:00 committee_full: Internal Market and Consumer Protection rapporteur: group: Verts/ALE name: TURMES Claude body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO body: EP responsible: False committee: ITRE date: 2009-09-16T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: Verts/ALE name: RIVASI Michèle body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE type: Committee report tabled for plenary, 1st reading/single reading
        • date: 2010-09-21T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20100921&type=CRE type: Debate in Parliament title: Debate in Parliament body: EP type: Debate in Parliament
        • date: 2010-09-22T00:00:00 docs: url: http://www.europarl.europa.eu/oeil/popups/sda.do?id=18371&l=en type: Results of vote in Parliament title: Results of vote in Parliament url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2010-331 type: Decision by Parliament, 1st reading/single reading title: T7-0331/2010 body: EP type: Results of vote in Parliament
        • date: 2010-11-29T00:00:00 body: CSL type: Council Meeting council: Agriculture and Fisheries meeting_id: 3050
        • date: 2010-11-29T00:00:00 body: EP/CSL type: Act adopted by Council after Parliament's 1st reading
        • date: 2010-12-15T00:00:00 body: CSL type: Final act signed
        • date: 2010-12-15T00:00:00 body: EP type: End of procedure in Parliament
        • date: 2010-12-31T00:00:00 type: Final act published in Official Journal docs: url: http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32010R1235 title: Regulation 2010/1235 url: http://eur-lex.europa.eu/JOHtml.do?uri=OJ:L:2010:348:SOM:EN:HTML title: OJ L 348 31.12.2010, p. 0001 url: http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexapi!prod!CELEXnumdoc&lg=EN&model=guicheti&numdoc=32010R1235R(01) title: Corrigendum to final act 32010R1235R(01) url: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2012:201:TOC title: OJ L 201 27.07.2012, p. 0138
        commission
        • body: EC dg: Health and Food Safety commissioner: DALLI John
        committees/0
        type
        Responsible Committee
        body
        EP
        associated
        False
        committee_full
        Environment, Public Health and Food Safety
        committee
        ENVI
        date
        2009-09-10T00:00:00
        rapporteur
        name: MCAVAN Linda group: Progressive Alliance of Socialists and Democrats abbr: S&D
        committees/0
        body
        EP
        responsible
        True
        committee
        ENVI
        date
        2009-09-10T00:00:00
        committee_full
        Environment, Public Health and Food Safety
        rapporteur
        group: S&D name: MCAVAN Linda
        committees/1
        type
        Former Responsible Committee
        body
        EP
        associated
        False
        committee_full
        Environment, Public Health and Food Safety
        committee
        ENVI
        date
        committees/1
        body
        EP
        responsible
        True
        committee_full
        Environment, Public Health and Food Safety
        committee
        ENVI
        committees/2
        type
        Committee Opinion
        body
        EP
        associated
        False
        committee_full
        Industry, Research and Energy
        committee
        ITRE
        date
        2009-09-16T00:00:00
        rapporteur
        name: RIVASI Michèle group: Greens/European Free Alliance abbr: Verts/ALE
        committees/2
        body
        EP
        responsible
        False
        committee
        IMCO
        date
        2009-09-28T00:00:00
        committee_full
        Internal Market and Consumer Protection
        rapporteur
        group: Verts/ALE name: TURMES Claude
        committees/3
        type
        Committee Opinion
        body
        EP
        associated
        False
        committee_full
        Internal Market and Consumer Protection
        committee
        IMCO
        date
        2009-09-28T00:00:00
        rapporteur
        name: TURMES Claude group: Greens/European Free Alliance abbr: Verts/ALE
        committees/3
        body
        EP
        responsible
        False
        committee_full
        Internal Market and Consumer Protection
        committee
        IMCO
        committees/4
        type
        Former Committee Opinion
        body
        EP
        associated
        False
        committee_full
        Industry, Research and Energy
        committee
        ITRE
        date
        committees/4
        body
        EP
        responsible
        False
        committee
        ITRE
        date
        2009-09-16T00:00:00
        committee_full
        Industry, Research and Energy
        rapporteur
        group: Verts/ALE name: RIVASI Michèle
        committees/5
        type
        Former Committee Opinion
        body
        EP
        associated
        False
        committee_full
        Internal Market and Consumer Protection
        committee
        IMCO
        date
        committees/5
        body
        EP
        responsible
        False
        committee_full
        Industry, Research and Energy
        committee
        ITRE
        council
        • body: CSL type: Council Meeting council: Agriculture and Fisheries meeting_id: 3050 url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=3050*&MEET_DATE=29/11/2010 date: 2010-11-29T00:00:00
        • body: CSL type: Council Meeting council: Employment, Social Policy, Health and Consumer Affairs meeting_id: 2980 url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=2980*&MEET_DATE=30/11/2009 date: 2009-11-30T00:00:00
        docs
        • date: 2008-12-10T00:00:00 docs: url: http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/sec/2008/2670/COM_SEC(2008)2670_EN.pdf title: SEC(2008)2670 url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=SECfinal&an_doc=2008&nu_doc=2670 title: EUR-Lex type: Document attached to the procedure body: EC
        • date: 2008-12-10T00:00:00 docs: url: http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/sec/2008/2671/COM_SEC(2008)2671_EN.pdf title: SEC(2008)2671 url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=SECfinal&an_doc=2008&nu_doc=2671 title: EUR-Lex type: Document attached to the procedure body: EC
        • date: 2009-04-22T00:00:00 docs: url: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:C:2009:229:TOC title: OJ C 229 23.09.2009, p. 0019 title: JOC_2009/C/229/04 summary: OPINION OF THE EUROPEAN DATA PROTECTION SUPERVISOR on the proposal for a Regulation of the European Parliament and of the Council amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and on the proposal for a Directive of the European Parliament and of the Council amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use. Recall : on 10 December 2008, the Commission adopted two proposals relating to the amendment of the actual pharmacovigilance system. The general intention of the two proposals is to remedy these weaknesses and to improve and strengthen the Community pharmacovigilance system with the overall objective of better protecting public health, ensuring proper functioning of the internal market and simplifying the current rules and procedures (see COD/2008/0260 ). The overall operation of the current pharmacovigilance system relies on the processing of personal data. These data are included in the adverse drug reactions reporting and can be considered as data relating to health of the persons concerned since they reveal information about drug use and associated health problems. Processing of such data is subject to strict data protection rules as laid down in Regulation (EC) No 45/2001 on the protection of individuals with regard to the processing of personal data by the Community institutions and bodies and on the free movement of such data and Directive 95/46/EC on the protection of individuals with regard to the processing of personal data and on the free movement of such data. Despite this, no reference to data protection is included in the current text of Regulation (EC) No 726/2004 and Directive 2001/83/EC, except for one specific reference in the Regulation. The EDPS regrets that data protection aspects are not considered within the proposed amendments and that he was not formally consulted on both proposals for amendments. The EDPS recommends that a reference to this opinion is included in the preamble of both proposals. Content of the Opinion : this Opinion will first proceed with a simplified explanation of the system of pharmacovigilance in the EU as it follows from Regulation (EC) No 726/2004 and Directive 2001/83/EC in their present state. Subsequently, the necessity of processing of personal data in the context of pharmacovigilance will be analysed. After this, the proposals of the Commission for improving the current and envisaged legal framework will be discussed and recommendations will be made on how to ensure and improve the data protection standards. Conclusions and recommendations : the EDPS takes the view that the lack of a proper assessment of the data protection implications of pharmacovigilance constitutes one of the weaknesses of the current legal framework set out by Regulation (EC) No 726/2004 and Directive 2001/83/EC . The current amendment of Regulation (EC) No 726/2004 and Directive 2001/83/EC should be seen as an opportunity to introduce data protection as a full-fledged and important element of pharmacovigilance. A general issue to be addressed thereby is the actual necessity of processing personal health data at all stages of the pharmacovigilance process. As explained in this Opinion, the EDPS seriously doubts this need and urges the legislator to reassess it at the different levels of the process. It is clear that the purpose of pharmacovigilance can in many cases be achieved by sharing information on adverse effects which is anonymous in the meaning of the data protection legislation. Duplication of reporting can be avoided through the application of well structured data reporting procedures already at national level. The proposed amendments envisage a simplified reporting system and a strengthening of the EudraVigilance database . The EDPS has explained that these amendments lead to increased risks for data protection, especially when it involves the direct reporting of patients to the EMEA or the EudraVigilance database. In this respect, the EDPS: strongly advocates a decentralised and indirect reporting system whereby communication to the European webportal is coordinated through using the national webportals; emphasises that privacy and security should be part of the design and implementation of a reporting system through the use of web-portals (‘privacy by design’); underlines that once data concerning health about identified or identifiable natural persons is processed, the person responsible for such processing should comply with all the requirements of the Community data protection legislation. More specifically, the EDPS recommends : to include a reference to this Opinion in the preamble of both proposals, to introduce in both Regulation (EC) No 726/2004 and Directive 2001/83/EC a recital stating the importance of data protection in the context of pharmacovigilance, with references to the relevant Community legislation; to introduce in Regulation (EC) No 726/2004 and Directive 2001/83/EC a new Article having a general nature which states that: (i) the provisions of Regulation (EC) No 726/2004 and Directive 2001/83/EC are without prejudice to the rights and obligations stemming from the provisions of Regulation (EC) No 45/2001 and Directive 95/46/EC respectively, with specific reference to Article 10 of Regulation (EC) No 45/2001 and Article 8 of Directive 95/46/EC respectively; (ii) identifiable health data shall only be processed when strictly necessary and parties involved should assess this necessity at every single stage of the pharmacovigilance process; to include in the proposed Article 24(2) of Regulation (EC) No 726/2004 a sentence stating that the accessibility of the EudraVigilance database shall be regulated in conformity with the rights and obligations stemming from the Community legislation on data protection; to add a paragraph to the proposed Article 24 stating that measures shall be put in place which ensure that the data subject can exercise his right of access to personal data concerning him as provided for by Article 13 of Regulation (EC) No 45/2001; to add to the proposed Article 101 of Directive 2001/83/EC a paragraph which states that in case of processing of personal data the individual shall be properly informed in accordance with Article 10 of Directive 95/46/EC; to include in the newly proposed Articles 25 and 26 of Regulation (EC) No 726/2004 and Article 106 of Directive 2001/83/EC, which deal with the development of a reporting system for adverse effects through the use of web- portals, an obligation to incorporate proper privacy and security measures at an even level across Member States, taking into account the basic principles of confidentiality, integrity, accountability and availability of data. type: Document attached to the procedure body: EDPS
        • date: 2009-06-10T00:00:00 docs: url: https://dm.eesc.europa.eu/EESCDocumentSearch/Pages/redresults.aspx?k=(documenttype:AC)(documentnumber:1023)(documentyear:2009)(documentlanguage:EN) title: CES1023/2009 type: Economic and Social Committee: opinion, report body: ESC
        • date: 2009-12-17T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE430.928 title: PE430.928 type: Committee draft report body: EP
        • date: 2010-02-24T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE431.040&secondRef=02 title: PE431.040 committee: IMCO type: Committee opinion body: EP
        • date: 2010-03-01T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE438.413 title: PE438.413 type: Amendments tabled in committee body: EP
        • date: 2010-04-16T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE430.771&secondRef=02 title: PE430.771 committee: ITRE type: Committee opinion body: EP
        • date: 2010-05-10T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2010-153&language=EN title: A7-0153/2010 type: Committee report tabled for plenary, 1st reading/single reading body: EP
        • date: 2010-10-13T00:00:00 docs: url: /oeil/spdoc.do?i=18371&j=0&l=en title: SP(2010)7193 type: Commission response to text adopted in plenary
        • date: 2010-12-15T00:00:00 docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=[%n4]%2F10&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC title: 00046/2010/LEX type: Draft final act body: CSL
        events
        • date: 2008-12-10T00:00:00 type: Legislative proposal published body: EC docs: url: http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2008/0664/COM_COM(2008)0664_EN.pdf title: COM(2008)0664 url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2008&nu_doc=664 title: EUR-Lex summary: PURPOSE: to improve the functioning of Community rules on the pharmacovigilance of medicinal products for human use, with the overall objectives of better protecting public health, ensuring proper functioning of the internal market and simplifying the current rules and procedures. PROPOSED ACT: Directive of the European Parliament and of the Council. CONTENT: it is estimated that 5% of all hospital admissions are due to an adverse drug reaction, that 5% of all hospital patients suffer an adverse drug reaction and adverse drug reactions are the fifth most common cause of hospital death. Some adverse reactions will only be detected after a medicine has been authorised and the full safety profile of medicinal products can only be known once they have entered the market. Community rules so far adopted have made a major contribution to the achievement of the objective that medicinal products authorised to be placed on the Community market are continuously monitored as regards their safety. However, in the light of the experience acquired and following an assessment by the Commission of the Community system of pharmacovigilance, it has become clear that new measures are necessary to improve the operation of the Community rules on the pharmacovigilance of medicinal products for human use. Therefore, the proposals aim at the strengthening and rationalizing the Community pharmacovigilance system of medicinal products for human use through the amendment of the two legal acts governing this field, i.e. Directive 2001/83/EC (see COD/2008/0260 ) and Regulation (EC) No 726/2004. The specific objectives are: providing for clear roles and responsibilities for the key responsible parties and clear obligations against which they perform their roles; rationalising EU decision-making on drug safety issues; strengthening medicines safety transparency and communication; strengthening companies' pharmacovigilance systems; ensuring the proactive and proportionate collection of high quality data relevant to the safety of medicines through risk management and structured data collection; involving stakeholders in pharmacovigilance; simplification of the current Community pharmacovigilance procedures. The key elements of the proposals can be summarised as follows: Clear roles and responsibilities : the key tasks of the Agency in the area of pharmacovigilance are overall maintained, but the Agency's coordinating role at the centre of the Community pharmacovigilance system is reinforced; the Member States should remain core to the operation of pharmacovigilance in the Community, with increased cooperation and work-sharing mechanisms; the pharmacovigilance responsibilities of marketing authorisation holders are also clarified, in particular as regards the scope of the obligation of marketing authorisation holders to continuously monitor the safety of products to ensure that all information available is brought to the attention of the authorities; a new scientific committee responsible for pharmacovigilance is created within the Agency: the Pharmacovigilance Risk Assessment Advisory Committee. This Committee is intended to play a key role in the pharmacovigilance assessments in the Community; the mandate of the coordination group composed of Member States representatives is enhanced; the Community procedure for the assessment of serious safety issues for nationally authorised products is stream-lined through clear and binding initiation criteria for the Member States. Transparency and communication in terms of drug safety issues : strengthening of the Eudravigilance database, which should become the single point of receipt of pharmacovigilance information for medicinal products for human use authorised in the Community; Community coordination of communication about safety issues and establishment of a European medicines safety web-portal; introduction of a new ‘key information' section in the summary of the product characteristics and the package leaflet which accompany every medicinal product placed on the Community market. Pharmacovigilance obligations of the marketing authorisation holder : the proposals simplify the requirement that a ‘detailed description of the pharmacovigilance system’ be submitted in marketing authorisation applications. In the marketing authorisation application, only key elements of the pharmacovigilance system should be submitted, but this is balanced with a requirement for companies to maintain a detailed pharmacovigilance system master file on site. Risk management planning and non-interventional safety studies : the establishment of a risk management system for each medicinal product to be newly authorised in the Community (or for existing products on the basis of safety concerns), which should be proportionate to the identified risks, potential risks, and the need for additional information on the medicinal product; the establishment of harmonised guiding principles and a procedure for the supervision of non-interventional post-authorisation safety studies (i.e. safety studies of authorised products that are not clinical trials), in particular to ensure that they are non promotional, and the follow-up of any safety data generated in such studies. Adverse drug reaction case reports : the proposals are intended to make reporting proportionate to risks, to empower patients to report their side effects, and to ensure that overdoses and medication errors are reported. The following has therefore been proposed: simplification of adverse reaction reporting by providing that all adverse reaction data are reported directly to the Eudravigilance database; requiring the Agency to assume the role of monitoring scientific literature by the Agency and to enter case reports of adverse effects into the Eudravigilance database; clarification of the definition of adverse drug reaction to make clear that companies report medication errors that result in an adverse reaction to the competent authorities for medicines and ensure that all the relevant Member State authorities share data; clarification of the legal basis for patients to report suspected adverse drug reactions. Periodic safety update reports and other safety related assessments : the proposals simplify periodic safety update report submission by industry and make it proportional to the knowledge about the safety/risk of the product. They introduce work-sharing mechanisms for the assessments, with a prominent role in all cases by the Pharmacovigilance Risk Assessment Advisory Committee, and faster updating of product information through the establishment of clear procedures.
        • date: 2009-01-13T00:00:00 type: Committee referral announced in Parliament, 1st reading/single reading body: EP
        • date: 2009-10-19T00:00:00 type: Committee referral announced in Parliament, 1st reading/single reading body: EP
        • date: 2009-11-30T00:00:00 type: Debate in Council body: CSL docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=2980*&MEET_DATE=30/11/2009 title: 2980 summary: On the basis of progress reports, the Presidency informed the Council of the state of play in the negotiations on two parts of the "pharmaceutical package": preventing falsified medicines from entering into the legal supply chain of medicinal products and the strengthening and rationalising of the current pharmacovigilance system. Under the Swedish Presidency, the preparatory bodies of the Council pursued their work with high priority on these two parts of the package. 1) Concerning the draft directive on preventing the entry into the legal supply chain of falsified medicinal products , the working group reached tentative agreement on a number of technical aspects, including: · the definition of "falsified medicinal products"; · the proposed definition of ''trading of medicinal products'' has been changed to ''brokering of medicinal products'' and amended, thereby clarifying which actors in the supply chain should be subject to the responsibilities of brokers. The proposed introduction of obligations for brokers aim to reinforce the traceability of medicinal products; · a clarification of the relationship between the proposed new provisions in Directive 2001/83/EC and Community legislation on intellectual property rights. Other elements of the proposal still need further discussion, notably with regard to the strengthening of controls of non active substances used in pharmaceuticals (excipients) and the proposed safety features aiming to render falsification more difficult. The proposal includes provisions requiring the accreditation of third party auditors of Good Manufacturing Practices and Good Distribution Practices. A majority of delegations object to accreditation, since they maintain that such a system could result in a transfer of responsibility from manufacturers and importers as well as make enforcement by national competent authorities more difficult. The Presidency has therefore proposed to delete the provisions regarding accreditation from the text. Some delegations have expressed an interest in the possibility of establishing third party accreditation at a national level. 2) Concerning the proposals for a regulation and a directive on strengthening the EU system for the safety monitoring of medicinal products ("pharmacovigilance"), the working group reached tentative agreement on a number of questions including: · a clarification of the relation between the proposed new provisions in Directive 2001/83/EC and Regulation (EC) 726/2004 on the one hand and the Community legislation on protection of personal data on the other hand; · a strengthening of the role of the Pharmacovigilance Risk Assessment Committee (PRAC) in relation to the Committee for Medicinal Products for Human Use and to the Coordination Group set up by Article 27 of Directive 2001/83/EC (CMD), including an obligation for these last two bodies to explain any differences in opinion compared to the PRAC; · a change in the composition of the PRAC and in the method for nominating the PRAC members so that all Member States will be represented; · the inclusion of a requirement for the Agency, in collaboration with the Member States and the Commission, to draw up functional specifications for the Eudravigilance database which will take account of the role and experience of national competent authorities for pharmacovigilance. The new reporting obligations to Eudravigilance will not apply until these specifications are met and to this end a transitional period is envisaged; · the legal status of CMD opinions and how they are implemented in Member States. Here, text redrafting proposals are under legal scrutiny. The Working Party has continued to discuss other central provisions of the proposals, mainly in relation to the Community Procedure and Referrals, the Recording and Reporting of adverse reactions, the Periodic Safety Update Reports and the Post Authorisation Safety Studies. A number of issues still require further examination, such as the recording and reporting of adverse reactions and the proposed list of medicinal products for human use under intensive monitoring. At this stage, all delegations have a general scrutiny reservation on the entire proposal while the Danish, Maltese and United Kingdom delegations have parliamentary scrutiny reservations. 3) With regard to the third part of the "pharmaceutical package", the proposals for a regulation and a directive concerning information for the general public on medicinal products, the Presidency recalled the strong concerns of many Member States. The Commission made it clear that it is prepared to show flexibility in order to find a common basis for the future negotiations.
        • date: 2010-04-27T00:00:00 type: Vote in committee, 1st reading/single reading body: EP summary: The Committee on the Environment, Public Health and Food Safety adopted the report by Linda MACAVAN (S&D, UK) on the proposal for a regulation of the European Parliament and of the Council amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. It recommended that the European Parliament’s position at first reading under the ordinary legislative procedure (formerly known as the codecision procedure) should be to amend the Commission proposal as follows: A Pharmacological Risk Assessment Committee (PRAC) with greater powers: in order to ensure harmonised responses across the Community to safety concerns regarding medicinal products for human use, the Committee for Medicinal Products for Human Use and the coordination group established by Directive 2001/83/EC on the Community code relating to medicinal products for human use should rely on the recommendation of the Pharmacovigilance Risk Assessment Committee on any question relating to the pharmacovigilance of medicinal products for human use. The CHMP shall adopt an opinion which differs from the recommendation of the Pharmacovigilance Risk Assessment Committee, only where there exist strong scientific and public health grounds for doing so. The CHMP shall explain such grounds in a justification to be annexed to its opinion. Post-authorisation safety and efficacy studies : after the granting of a marketing authorisation, the Agency may require a marketing authorisation holder to conduct a post-authorisation safety study, or post-authorisation safety and efficacy studies where important questions relating to the efficacy of a product remain; or when scientific advances in the understanding of the disease or in the clinical methodology would significantly change previous efficacy evaluations. For this purpose the Commission shall provide guidelines. The Commission shall also, based on data received from the Agency and Member States, produce a report focusing on the concept of Clinical Effectiveness, studies and data required and methodologies for assessing it. Renewal of marketing authorisation : the committee deleted the words « insufficient exposure to the product » as a criterion for restricting renewal to a five-year period. The benefits of a harmonised and simplified approach pursued in the current proposal should be preserved. The new proposal should not regress on improvements introduced by the previous revision of the medicines legislation which aimed at reducing the number of renewal procedures. Pharmacovigilance: the report adds that Member States shall support the development of the expertise of national and regional pharmacovigilance centres. National competent authorities should collect the reports from those centres and should then transfer data to the Eudravigilance database. The Agency shall work together with all stakeholders, including research institutions, healthcare professionals, and patient and consumer organisations, in order to define the "appropriate level of access" to the Eudravigilance database. The Agency, in collaboration with the Member States and all relevant stakeholders, shall develop standard structured forms and procedures, including web-based forms, for the reporting of suspected adverse reactions by health-care professionals and patients. To ensure the identification of biological medicinal products prescribed, dispensed or sold in the territory of the Union, the standard forms and procedures shall include the name of the MAH (marketing authorisation holder), the INN(international non-proprietary name), the name of the medicinal product and the batch number. The Agency shall also make available to the public other means for patients to report undesirable effects, such as a dedicated telephone number or special email address All citizens of the Union shall have the option of submitting online declarations in their mother tongue. The Agency must make public the declaration of committee members’ interests and agendas for, and records of, each meeting, accompanied by decisions taken. It must also make public the link to the Agency's EudraPharm database which must include the most up-to-date electronic version of the package leaflet and summary of product characteristics for all existing and new medicinal products authorised in accordance with the Regulation and with Directive 2001/83/EC, as well as a link to the Agency's European Public Assessment Report summary database which publishes information sheets on centrally authorised products. These two resources shall be publicised to the general public by the Agency or the competent authorities. The Agency shall monitor all medical literature for reports of suspected adverse reactions to medicinal products for human use containing well established active substances. Assessment report following periodic safety update reports : PRAAC shall formulate a recommendation for the Committee for Medicinal Products for Human Use on the basis of the assessment report. The CHMP shall adopt an opinion which differs from the recommendation of the Pharmacovigilance Risk Assessment Committee, only where there exist strong scientific and public health grounds for doing so. The CHMP shall explain such grounds in a justification to be annexed to its opinion. Public hearings : in assessing updates to the risk management systems, the Pharmacovigilance Risk Assessment Committee may hold a public hearing. Public hearings shall be announced by means of the European medicines safety web-portal. The announcement shall include information on how marketing authorisation holders and the public can participate. The Agency shall provide the opportunity, to all those who request it, to participate in the hearing either in person or through the use of web-based technology. Where a marketing authorisation holder or another person intending to submit information has commercially confidential data relevant to the issue of the procedure, he may request that he be allowed to present those data to the Pharmacovigilance Risk Assessment Committee in a non-public hearing. Lastly, the committee amended provisions relating to the composition of the Pharmacovigilance Risk Assessment Advisory Committee and stressed that its independence must be guaranteed.
        • date: 2010-05-10T00:00:00 type: Committee report tabled for plenary, 1st reading/single reading body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2010-153&language=EN title: A7-0153/2010
        • date: 2010-09-21T00:00:00 type: Debate in Parliament body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20100921&type=CRE title: Debate in Parliament
        • date: 2010-09-22T00:00:00 type: Results of vote in Parliament body: EP docs: url: https://oeil.secure.europarl.europa.eu/oeil/popups/sda.do?id=18371&l=en title: Results of vote in Parliament
        • date: 2010-09-22T00:00:00 type: Decision by Parliament, 1st reading/single reading body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2010-331 title: T7-0331/2010 summary: The European Parliament adopted by 559 votes to 7, with 12 abstentions, a legislative resolution on the proposal for a regulation of the European Parliament and of the Council amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. The Parliament adopted its position at first reading under the ordinary legislative procedure (formerly known as the codecision procedure). The amendments adopted in plenary are the result of a compromise reached between the European Parliament and the Council. They amend the Commission’s position as follows: Strengthened Risk Assessment Committee : in order to ensure harmonised responses across the Union to safety concerns regarding medicinal products for human use, the Committee for Medicinal Products for Human Use and the coordination group established by Directive 2001/83/EC on the Community code relating to medicinal products for human use should rely on the recommendation of the Pharmacovigilance Risk Assessment Committee on any question relating to the pharmacovigilance of medicinal products for human use. It is appropriate that the Pharmacovigilance Risk Assessment Committee should give a recommendation as part of any Union-wide post-authorisation assessment based on pharmacovigilance data relating to medicinal products as well as on the agreement and monitoring of the risk management systems. Such Union-wide assessments should follow the procedures laid down in Directive 2001/83/EC also for medicinal products that were authorised through the centralised procedure. Market authorisation : post authorisation efficacy and safety studies : the amended text stipulates that it is necessary from a public health perspective to complement the data available at the time of authorisation with additional data about the safety and, in certain cases, also about the efficacy of medicinal products authorised. The Commission should therefore be empowered to require the marketing authorisation holder to conduct post-authorisation studies on safety and on efficacy. It should be possible to impose this requirement at the time of granting the marketing authorisation or later, and it should be part of the marketing authorisation. These additional studies may be aimed at collecting data to enable the assessment of safety or efficacy of medicinal products in everyday medical practice. The supervisory authorities for pharmacovigilance may, as considered necessary, conduct pre-authorisation pharmacovigilance inspections to verify the accuracy and successful implementation of the pharmacovigilance system as described by the applicant in support of the application. Products authorised subject to additional monitoring : some medicinal products are authorised subject to additional monitoring. This includes all medicinal products with a new active substance and biological medicinal products including biosimilars for which pharmacovigilance activities are prioritised. This may also apply, at the request of the competent authorities, to specific products, subject to the requirement to conduct a post-authorisation safety study or subject to conditions or restrictions with regard to the safe and effective use of the medicinal product that will be specified in the risk management plan. Risk management plans are normally required for new active substances, biosimilars, medicinal products for paediatric use and for products involving a significant change in the marketing authorisation, including a new manufacturing process of a biotechnologically-derived product. Products subject to additional monitoring should be identified as such by a black symbol , which will be selected by the Commission on a recommendation by the Pharmacovigilance Risk assessment Committee, and a relevant standard explanatory sentence on the summary of product characteristics and on the patient information leaflet, and a publicly available list of such medicinal products should be kept up to date by the Agency. Data protection : this Regulation shall apply without prejudice to Directive 95/46/EC on the protection of individuals with regard to the processing of personal data and on the free movement of such data and Regulation (EC) No 45/2001 on the protection of individuals with regard to the processing of personal data by the Union institutions and bodies and on the free movement of such data. In order to detect, assess, understand and prevent adverse reactions, identify and take actions to reduce risks and increase benefits from medicinal products for the purpose of safeguarding public health, it should be possible to process personal data within the Eudravigilance system while respecting EU data protection legislation. Tasks of the Agency : the amended text specifies that the Regulation and Directive amending Directive 2001/83/EC on the Community Code relating to medicinal products for human use widen the task of the Agency with regard to pharmacovigilance, including literature monitoring, improved information technology tools and provision of more information to the general public. The Agency should be enabled to fund these activities from fees paid by marketing authorisation holders. These fees should not cover tasks carried out by national competent authorities for which such authorities charge fees in accordance with the provisions of Directive 2001/83/EC. Uniform conditions : a recital states that uniform conditions be established as concerns the contents and maintenance of the pharmacovigilance system master file, as well the minimum requirements of the quality system for the performance of pharmacovigilance activities by the national competent authorities and marketing authorisation holders, the use of internationally agreed terminology, formats and standards for the conduct of pharmacovigilance, and the minimum requirements for the monitoring of data in the Eudravigilance database to determine whether there are new or changed risks. The format and content of electronic transmission of suspected adverse reactions by Member States and marketing authorisation holders, the format and content of electronic periodic safety update reports and risk management plans and the format of protocols, abstracts and final study reports for the post-authorisation safety studies should also be established. In this respect, pending the adoption of a new Regulation based on Article 291 of the TFEU, Council Decision 1999/468/EC of 28 June 1999 laying down the procedures for the exercise of implementing powers conferred on the Commission continues to apply, with the exception of the regulatory procedure with scrutiny, which is not applicable. Executive Director of the Agency : the Executive Director of the Agency shall ensure appropriate coordination between the Committee for Advanced Therapies and the other Committees of the Agency, in particular the Committee for Medicinal Products for Human Use, the Pharmacovigilance Risk Assessment Committee and the Committee for Orphan Medicinal Products, their working parties and any other scientific advisory groups.
        • date: 2010-11-29T00:00:00 type: Act adopted by Council after Parliament's 1st reading body: EP/CSL
        • date: 2010-12-15T00:00:00 type: Final act signed body: CSL
        • date: 2010-12-15T00:00:00 type: End of procedure in Parliament body: EP
        • date: 2010-12-31T00:00:00 type: Final act published in Official Journal summary: Corrigendum to Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products (Regulation first published in the OJ L 348 of 31.12.2010). Article 1(7) should read: In Article 16, paragraphs 1, 2 and 3 are replaced by the following: 3. The marketing authorisation holder shall ensure that the product information is kept up to date with the current scientific knowledge including the conclusions of the assessment and recommendations made public by means of the European medicines web-portal established in accordance with Article 26. 3a. In order to be able to continuously assess the risk-benefit balance, the Agency may at any time ask the marketing authorisation holder to forward data demonstrating that the risk-benefit balance remains favourable. The marketing authorisation holder shall answer fully and promptly any such request. The Agency may at any time ask the marketing authorisation holder to submit a copy of the pharmacovigilance system master file. The marketing authorisation holder shall submit the copy at the latest seven days after receipt of the request. docs: title: Regulation 2010/1235 url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32010R1235 title: OJ L 348 31.12.2010, p. 0001 url: https://eur-lex.europa.eu/JOHtml.do?uri=OJ:L:2010:348:SOM:EN:HTML title: Corrigendum to final act 32010R1235R(01) url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexapi!prod!CELEXnumdoc&lg=EN&model=guicheti&numdoc=32010R1235R(01) title: OJ L 201 27.07.2012, p. 0138 url: https://eur-lex.europa.eu/JOHtml.do?uri=OJ:L:2012:201:SOM:EN:HTML
        other
        • body: CSL type: Council Meeting council: Former Council configuration
        • body: EC dg: url: http://ec.europa.eu/dgs/health_consumer/index_en.htm title: Health and Consumers commissioner: DALLI John
        procedure/Modified legal basis
        Old
        Rules of Procedure of the European Parliament EP 150
        New
        Rules of Procedure EP 150
        procedure/dossier_of_the_committee
        Old
        ENVI/7/00162
        New
        • ENVI/7/00162
        procedure/final/url
        Old
        http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32010R1235
        New
        https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32010R1235
        procedure/instrument
        Old
        Regulation
        New
        • Regulation
        • Amending Regulation (EC) No 726/2004, Community procedures 2001/0252(COD) Amending Regulation (EC) No 1394/2007 2005/0227(COD) See also 2008/0260(COD)
        procedure/subject
        Old
        • 4.20.04 Pharmaceutical products and industry
        • 4.20.05 Health legislation and policy
        • 4.60.08 Safety of products and services, product liability
        New
        4.20.04
        Pharmaceutical products and industry
        4.20.05
        Health legislation and policy
        4.60.08
        Safety of products and services, product liability
        procedure/summary
        • Amending Regulation (EC) No 1394/2007
        • Amending Regulation (EC) No 726/2004, Community procedures
        • See also
        procedure/title
        Old
        Medicinal products for human use: pharmacovigilance of products
        New
        Medicinal products for human use: pharmacovigilance of products
        activities/0/docs/0/url
        Old
        http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2008/0664/COM_COM(2008)0664_EN.pdf
        New
        http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2008/0664/COM_COM(2008)0664_EN.pdf
        links/European Commission/title
        Old
        PreLex
        New
        EUR-Lex
        activities
        • date: 2008-12-10T00:00:00 docs: url: http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2008/0664/COM_COM(2008)0664_EN.pdf celexid: CELEX:52008PC0664:EN type: Legislative proposal published title: COM(2008)0664 type: Legislative proposal published body: EC commission: DG: url: http://ec.europa.eu/dgs/health_consumer/index_en.htm title: Health and Consumers Commissioner: DALLI John
        • date: 2009-01-13T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading committees: body: EP responsible: True committee: ENVI date: 2009-09-10T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: S&D name: MCAVAN Linda body: EP responsible: True committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: False committee: IMCO date: 2009-09-28T00:00:00 committee_full: Internal Market and Consumer Protection rapporteur: group: Verts/ALE name: TURMES Claude body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO body: EP responsible: False committee: ITRE date: 2009-09-16T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: Verts/ALE name: RIVASI Michèle body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE
        • date: 2009-10-19T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading committees: body: EP responsible: True committee: ENVI date: 2009-09-10T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: S&D name: MCAVAN Linda body: EP responsible: True committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: False committee: IMCO date: 2009-09-28T00:00:00 committee_full: Internal Market and Consumer Protection rapporteur: group: Verts/ALE name: TURMES Claude body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO body: EP responsible: False committee: ITRE date: 2009-09-16T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: Verts/ALE name: RIVASI Michèle body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE
        • body: CSL meeting_id: 2980 docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=2980*&MEET_DATE=30/11/2009 type: Debate in Council title: 2980 council: Employment, Social Policy, Health and Consumer Affairs date: 2009-11-30T00:00:00 type: Council Meeting
        • date: 2010-04-27T00:00:00 body: EP committees: body: EP responsible: True committee: ENVI date: 2009-09-10T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: S&D name: MCAVAN Linda body: EP responsible: True committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: False committee: IMCO date: 2009-09-28T00:00:00 committee_full: Internal Market and Consumer Protection rapporteur: group: Verts/ALE name: TURMES Claude body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO body: EP responsible: False committee: ITRE date: 2009-09-16T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: Verts/ALE name: RIVASI Michèle body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE type: Vote in committee, 1st reading/single reading
        • date: 2010-05-10T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2010-153&language=EN type: Committee report tabled for plenary, 1st reading/single reading title: A7-0153/2010 body: EP committees: body: EP responsible: True committee: ENVI date: 2009-09-10T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: S&D name: MCAVAN Linda body: EP responsible: True committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: False committee: IMCO date: 2009-09-28T00:00:00 committee_full: Internal Market and Consumer Protection rapporteur: group: Verts/ALE name: TURMES Claude body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO body: EP responsible: False committee: ITRE date: 2009-09-16T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: Verts/ALE name: RIVASI Michèle body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE type: Committee report tabled for plenary, 1st reading/single reading
        • date: 2010-09-21T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20100921&type=CRE type: Debate in Parliament title: Debate in Parliament body: EP type: Debate in Parliament
        • date: 2010-09-22T00:00:00 docs: url: http://www.europarl.europa.eu/oeil/popups/sda.do?id=18371&l=en type: Results of vote in Parliament title: Results of vote in Parliament url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2010-331 type: Decision by Parliament, 1st reading/single reading title: T7-0331/2010 body: EP type: Results of vote in Parliament
        • date: 2010-11-29T00:00:00 body: CSL type: Council Meeting council: Agriculture and Fisheries meeting_id: 3050
        • date: 2010-11-29T00:00:00 body: EP/CSL type: Act adopted by Council after Parliament's 1st reading
        • date: 2010-12-15T00:00:00 body: CSL type: Final act signed
        • date: 2010-12-15T00:00:00 body: EP type: End of procedure in Parliament
        • date: 2010-12-31T00:00:00 type: Final act published in Official Journal docs: url: http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32010R1235 title: Regulation 2010/1235 url: http://eur-lex.europa.eu/JOHtml.do?uri=OJ:L:2010:348:SOM:EN:HTML title: OJ L 348 31.12.2010, p. 0001 url: http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexapi!prod!CELEXnumdoc&lg=EN&model=guicheti&numdoc=32010R1235R(01) title: Corrigendum to final act 32010R1235R(01) url: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2012:201:TOC title: OJ L 201 27.07.2012, p. 0138
        committees
        • body: EP responsible: True committee: ENVI date: 2009-09-10T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: S&D name: MCAVAN Linda
        • body: EP responsible: True committee_full: Environment, Public Health and Food Safety committee: ENVI
        • body: EP responsible: False committee: IMCO date: 2009-09-28T00:00:00 committee_full: Internal Market and Consumer Protection rapporteur: group: Verts/ALE name: TURMES Claude
        • body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO
        • body: EP responsible: False committee: ITRE date: 2009-09-16T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: Verts/ALE name: RIVASI Michèle
        • body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE
        links
        National parliaments
        European Commission
        other
        • body: CSL type: Council Meeting council: Former Council configuration
        • body: EC dg: url: http://ec.europa.eu/dgs/health_consumer/index_en.htm title: Health and Consumers commissioner: DALLI John
        procedure
        dossier_of_the_committee
        ENVI/7/00162
        reference
        2008/0257(COD)
        instrument
        Regulation
        legal_basis
        stage_reached
        Procedure completed
        summary
        subtype
        Legislation
        Modified legal basis
        Rules of Procedure of the European Parliament EP 150
        title
        Medicinal products for human use: pharmacovigilance of products
        type
        COD - Ordinary legislative procedure (ex-codecision procedure)
        final
        subject